Clover Biopharmaceuticals (HKG:2197) reported 101.3 million yuan in attributable loss for the first half of 2025, widening from a loss of 95.1 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.
Loss per share was 0.08 yuan, unchanged from last year.
The vaccine company generated 3.3 million yuan in revenue during the period, figures showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments